Literature DB >> 3236100

Developmental aspects of phenobarbital dosage requirements in newborn infants with seizures.

M C Nahata1, T Masuoka, R C Edwards.   

Abstract

Although phenobarbital is the most widely used drug to control seizures, dosage guidelines are not available for infants of varying gestational ages. The primary objective of this study was to develop age specific dosage guidelines for phenobarbital in newborn infants with seizures. Fifty-one patients (27 premature infants, gestational ages 27 to 38 weeks; 24 term infants) receiving phenobarbital, 3 to 6 mg/kg/d were studied during the first month of life. Multiple serum concentrations were determined in each patient during extended therapy. Trough serum concentration of phenobarbital ranged from 12.5 to 50.2 mcg/mL. Phenobarbital serum concentrations were within therapeutic range (15 to 40 mcg/mL) in 99 of 114 measurements at a maintenance dose of 3.5 to 4.5 mg/kg/d. The remaining 15 measurements were made in infants, greater than 35 weeks' gestation and required phenobarbital doses of 4.0 to 5.0 mg/kg/d to achieve therapeutic serum concentration. These data suggest that the initial maintenance dose of phenobarbital during the first month of life should be 3.5 to 4.5 mg/kg/d in infants less than or equal to 35 weeks and 4.0 to 5.0 mg/kg/d in those greater than 35 weeks' gestation. Term infants with asphyxia had higher trough serum concentration than those without asphyxia (P less than 0.005). In nine infants, trough serum concentration normalized for dose decreased substantially during a 3-weeks period (P less than 0.0005). This suggests that phenobarbital serum concentration should be monitored frequently during the first month of life.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3236100

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  4 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 2.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

3.  Can we safely administer the recommended dose of phenobarbital in very low birth weight infants?

Authors:  Osman Oztekin; Salih Kalay; Gonul Tezel; Mustafa Akcakus; Nihal Oygur
Journal:  Childs Nerv Syst       Date:  2013-04-05       Impact factor: 1.475

Review 4.  What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?

Authors:  Martin Šíma; Danica Michaličková; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.